Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Immunome Inc
IMNM | US
24.63
USD1.37
5.89%
IMNM | US
About Immunome Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
24.63
Open
23.85
High
24.81
Low
23.53
Immunome Inc. a biopharmaceutical company discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01 an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton Pennsylvania.
View LessIMNM | US
Risk
61.9
Sharpe
3.17
Luna's Score
52/100
Recommendation
Hold
Luna says (IMNM | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
45.1%1 month
61.9%3 months
56.4%6 months
68.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.86
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-0.72
Ent. to rev.
41.77
PEG
-
Other Fundamentals
EBITDA
-71.56M
MarketCap
1.48B
MarketCap(USD)
1.48B
Div. yield
-
Op. margin
-1.43K
Erngs. growth
-
Rev. growth
-44.50
Ret. on equity
-199.56
Short ratio
16.50
Short perc.
22.69
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.03
Range1M
5.65
Range3M
8.49
Volumes: Market Activity
Rel. volume
0.71
Price X volume
24.42M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.72 | - | Cheaper |
| Ent. to Revenue | 41.77 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 56.44 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.48B | - | Emerging |
